Completed PHASE3 INTERVENTIONAL NCT00376883

Pamidronate Prophylaxis in Multiple Myeloma 30 mg/Month Versus 90 mg/Month

The Effect of i.v. Bisphosphonate on Health-Related Quality of Life and Skeletal Morbidity for Newly Diagnosed Treatment Demanding Multiple Myeloma. A Prospective Randomised Double Blinded Dose-Effective Study With Cost-Utility Analysis.

Sponsor: Nordic Cancer Union

Conditions Multiple Myeloma

Interventions pamidronate

Updated 6 times since 2017 Last updated: Jan 3, 2007 Started: Jan 31, 2000 Completion: Oct 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00376883, this PHASE3 trial focuses on Multiple Myeloma and remains completed. Sponsored by Nordic Cancer Union, it has been updated 6 times since 2000, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jan 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Nordic Cancer Union
Nordic Myeloma Study Group

Data source: Nordic Myeloma Study Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aalborg, Denmark , Aarhus, Denmark , Bergen, Norway , Gothenburg, Sweden , Herlev, Denmark , København Ø, Denmark , Linköping, Sweden , Malmo, Sweden , Oslo, Norway , Tromsø, Norway and 4 more locations